Greetings!
I just got the latest Oklahoma University IC Health Matters Newsletter in the mail and they're announcing a new IC study for BCG.
I sure hope something positive comes from this study!
Derrick
===================================
IC research has just received notice from the NIH that the BCG study will begin enrollment. BCG is a live, but weakened form of cow tuberculosis bacteria. BCG has been used worldwide as a vaccine intended to treat tuberculosis, and has also been successfully used to treat patients with bladder cancer.
In a smaller study at William Beaumont Hospital in Royal Oak Michigan, BCG was given to 35 diagnosed IC patients following much the same methods as will be done in this study. The clinical response was a 60% positive response rate compared to those patients who received placebo (did not actually receive the active drug) and for whom the response rate was only 27%.
Our study involves administering six weekly instillations via catheter into the bladder gollowed by six months of follow-up. If at the end of the follow-up period, the patient is not better, the patient will be offered the option of receiving active BCG (no placebo will be used). The second series of treatments will occur on the same schedule as the first series followed by an additional six-month period of follow-up.
In order to participate in the study, the patient must have a diagnosis of IC as proven by a cysto/hydro. The patient cannot currently be taking Elmiron - must be off this medication for four weeks before beginning the eligibility process.
We are truly excited about the study, and would enjoy sharing the details of patient participation with you. If you have questions or an interest in participating in the study, please call Lynda Kelsey or Karen Mataranglo at (405) 271-6900.
I just got the latest Oklahoma University IC Health Matters Newsletter in the mail and they're announcing a new IC study for BCG.
I sure hope something positive comes from this study!
Derrick
===================================
IC research has just received notice from the NIH that the BCG study will begin enrollment. BCG is a live, but weakened form of cow tuberculosis bacteria. BCG has been used worldwide as a vaccine intended to treat tuberculosis, and has also been successfully used to treat patients with bladder cancer.
In a smaller study at William Beaumont Hospital in Royal Oak Michigan, BCG was given to 35 diagnosed IC patients following much the same methods as will be done in this study. The clinical response was a 60% positive response rate compared to those patients who received placebo (did not actually receive the active drug) and for whom the response rate was only 27%.
Our study involves administering six weekly instillations via catheter into the bladder gollowed by six months of follow-up. If at the end of the follow-up period, the patient is not better, the patient will be offered the option of receiving active BCG (no placebo will be used). The second series of treatments will occur on the same schedule as the first series followed by an additional six-month period of follow-up.
In order to participate in the study, the patient must have a diagnosis of IC as proven by a cysto/hydro. The patient cannot currently be taking Elmiron - must be off this medication for four weeks before beginning the eligibility process.
We are truly excited about the study, and would enjoy sharing the details of patient participation with you. If you have questions or an interest in participating in the study, please call Lynda Kelsey or Karen Mataranglo at (405) 271-6900.
Comment